Coronavirus disease 2019 (COVID-19) caused by SARS-CoV-2 is an ongoing viral
pandemic marked by increased risk of thrombotic events. However, the role of platelets in …

Globally, there have been close to 130 million reported cases of coronavirus disease 2019
(COVID-19) as of 2nd April 2021, with 2.8 million deaths documented [1]. In order to reduce …

Introduction: Thromboembolic events are one of the important complications in COVID-19
patients, especially in severe cases. Aspirin affects platelet function by irreversibly inhibiting …

There is growing evidence that thrombotic and inflammatory pathways contribute to the
severity of COVID-19. Common medications such as aspirin, that mitigate these pathways …

The coronavirus SARS-CoV2 disease (COVID-19) is connected with significant morbidity
and mortality (3.4%), disorders in hemostasis, including coagulopathy, activation of platelets …

Hypercoagulability and thrombosis caused by coronavirus disease 2019 (COVID‐19) are
related to the higher mortality rate. Because of limited data on the antiplatelet effect, we …

Coronavirus disease 2019 (COVID-19) induces a hypercoagulatory state that frequently
leads to thromboembolic complications. Whereas anticoagulation is associated with …

Abstract Coronavirus disease-2019 (COVID-19) caused by SARS-CoV-2 is an ongoing viral
pandemic marked by increased risk of thrombotic events. However, the role of platelets in …

'An aspirin a day keeps the heart attack away', is this also true in the prevention of thrombotic
events associated with COVID-19? The rising COVID-19 pandemic has led to much work in …

Background Repurposing the use of aspirin to treat hospitalized patients with COVID-19 is a
sensible approach. However, several previous studies showed conflicting results. This meta …